Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
3.62 | -2.43% | -0.09 |
MRNS closed down 2.43 percent on Friday, December 14, 2018, on 1.56 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical MRNS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 14 | MACD Bearish Signal Line Cross | Bearish | 0.00% |
| Dec 14 | Calm After Storm | Range Contraction | 0.00% |
| Dec 14 | Narrow Range Bar | Range Contraction | 0.00% |
| Dec 14 | NR7 | Range Contraction | 0.00% |
| Dec 14 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Dec 14 | Stochastic Reached Oversold | Weakness | 0.00% |
| Dec 14 | Inside Day | Range Contraction | 0.00% |
| Dec 14 | Wide Bands | Range Expansion | 0.00% |
| Dec 14 | Down 3 Days in a Row | Weakness | 0.00% |
| Dec 14 | Down 4 Days in a Row | Weakness | 0.00% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-10-30
- Sector: Healthcare
- Industry: Pharmaceuticals
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRNS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 10.54 |
| 52 Week Low | 3.31 |
| Average Volume | 1,279,900 |
| 200-Day Moving Average | 5.879 |
| 50-Day Moving Average | 5.2698 |
| 20-Day Moving Average | 4.506 |
| 10-Day Moving Average | 4.647 |
| Average True Range | 0.5423 |
| ADX | 20.92 |
| +DI | 18.3683 |
| -DI | 28.346 |
| Chandelier Exit (Long, 3 ATRs ) | 4.3731 |
| Chandelier Exit (Short, 3 ATRs ) | 4.9969 |
| Upper Bollinger Band | 5.4107 |
| Lower Bollinger Band | 3.6013 |
| Percent B (%b) | 0.01 |
| BandWidth | 40.155348 |
| MACD Line | -0.2734 |
| MACD Signal Line | -0.2352 |
| MACD Histogram | -0.0382 |
| Fundamentals | Value |
|---|---|
| Market Cap | 94.39 Million |
| Num Shares | 26.1 Million |
| EPS | -1.10 |
| Price-to-Earnings (P/E) Ratio | -3.29 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 7.28 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.98 | ||||
| Resistance 3 (R3) | 4.01 | 3.92 | 3.92 | ||
| Resistance 2 (R2) | 3.92 | 3.83 | 3.91 | 3.90 | |
| Resistance 1 (R1) | 3.77 | 3.77 | 3.85 | 3.74 | 3.88 |
| Pivot Point | 3.68 | 3.68 | 3.72 | 3.67 | 3.68 |
| Support 1 (S1) | 3.53 | 3.59 | 3.61 | 3.50 | 3.36 |
| Support 2 (S2) | 3.44 | 3.53 | 3.43 | 3.34 | |
| Support 3 (S3) | 3.29 | 3.44 | 3.32 | ||
| Support 4 (S4) | 3.26 |
